Drug intelligence / Profile preview

NM-501

Development stage: Preclinical
Lead developer: Neuramedy
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics

Overview

NM-501 is a diagnostic agent under development by Neuramedy for the detection of central nervous system (CNS) disorders. It is designed to target alpha-synuclein, a protein implicated in neurodegenerative diseases such as Parkinson’s disease and other synucleinopathies. The drug is classified as a radiopharmaceutical and diagnostic agent, intended to aid in the diagnosis rather than treatment of CNS conditions. As of the latest updates, NM-501 remains in early research stages with its highest R&D status at Discovery[1][2].

Targets

SNCA (Alpha-synuclein)

Beyond the preview

Go deeper on NM-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM-501.

Explore the full profile